Xilio reports Q4/FY 2024 results; cash $55.3M, AbbVie collaboration adds $52M upfront

Xilio Therapeutics, Inc.

Net loss of $13.1M in Q4 2024, $58.2M for FY 2024; license revenue $6.3M from Gilead deal.
Cash $55.3M at Dec 31, 2024; plus $52M AbbVie upfront in Q1 2025 extends runway into Q1 2026.
Vilastobart Phase 2 in MSS CRC: 27% ORR in patients without liver metastases; colitis 5%.
Collaboration with AbbVie: up to $2.1B total payments plus royalties; develop masked T cell engagers.
Plan to nominate development candidates for PSMA (Q3 2025), CLDN18.2 (Q4 2025), STEAP1 (H1 2026).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.